treatment of Obstructive Sleep Apnea Obstructive Sleep Apnea
tiny device
line treatment
treatment compliance monitoring
common sleep disorder
Ultra-small implanted neurostimulation device
Nyxoah's disruptive neurostimulation device
effects
activation chip
product development
key development
lifelong disease
system efficacy
increased risk of heart attack
invasive surgery
public healthcare costs
lower risk of infection
annual economic costs
daytime sleepiness
cardiac arrhythmia
stroke
world's
depression
patients
patient outcome
regualatory standards
social security agencies
obese cohorts
physicians
poor neurocognitive performance
clinical trials
industrialization plan
chronic health impacts
cloud
Europe
closed feedback loop
mortality
noisy machine
major problem
therapeutic options
nerve
useful information
constant pressure
scale
neurostimulator implantations
pulse
tissue resistance
CPAP
reimbursement
needs
disposable smart patch
Phase
project
company
app
cardiovascular morbidity
mask
people
burnout
users
drawbacks
year